Only 4 patient (23.5%) were with better pathology types (one DCIS, two mucinous carcinoma and one invasive lobular carcinoma) and 10 patients (59%) were hormone receptor (ER or PR) positive. This evidence concerns the gene PGR and ductal breast carcinoma in situ.